REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 15:45 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
August 28, 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Ozempic®, Wegovy®...
New Partnerships with Texas Family Fitness and UFC Gym Offer Members Exclusive Access to GLP-1 Weight Loss Programs
August 27, 2024 09:13 ET
|
NexgenMD360
NexgenMD360's FDA-approved rapid weight loss programs using Semaglutide & Tirzepatide deliver 20%+ weight loss results for men and women nationwide.
Sesame, America’s Low-Cost Leader in Healthcare, Makes Compounded Semaglutide Available to Eligible Patients “At Cost,” with no Retail Price Markup
August 21, 2024 09:00 ET
|
Sesame
NEW YORK CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced the launch of “Success by...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
August 09, 2024 08:15 ET
|
Mangoceuticals, Inc.
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
New Weight Loss Drugs Pose Anesthesia Risk, according to Journal of American Physicians and Surgeons
June 06, 2024 13:02 ET
|
Association of American Physicians and Surgeons
Weight loss drugs such as semaglutide impede stomach emptying, creating a significant risk from anesthesia. The effect may last for up to two months
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members
April 02, 2024 10:59 ET
|
Sesame
NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, today unveiled an...
Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester
March 06, 2024 06:00 ET
|
Research Nester
New York , March 06, 2024 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis treatment market size is predicted to expand at 18% CAGR between 2023 and 2035. The market is projected to...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 19, 2024 16:53 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...